Published in final edited form as:

Stroke. 2015 August ; 46(8): 2075–2080. doi:10.1161/STROKEAHA.115.009861.

Proteinuria, but not eGFR, predicts stroke risk in chronic kidney disease: the chronic renal insufficiency cohort (CRIC) study

Danielle K. Sandsmark, MD, PhD^{1,*}, Steven R. Messé, MD¹, Xiaoming Zhang, MS², Jason Roy, PhD², Lisa Nessel, MSS, MLSP², Lotuce Lee Hamm, MD³, Jiang He, MD, PhD⁴, Edward J. Horwitz, MD⁵, Bernard G. Jaar, MD, MPH⁶, Radhakrishna R. Kallem, MD, MPH⁷, John W. Kusek, PhD⁸, Emile R. Mohler III, MD⁹, Anna Porter, MD¹⁰, Stephen L. Seliger, MD, MS¹¹, Stephen M. Sozio, MD, MHS¹², Raymond R. Townsend, MD⁷, Harold I. Feldman, MD, MSCE², Scott E. Kasner, MD¹, and the CRIC Study Investigators

¹Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA

²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA

³Department of Medicine, Tulane University, New Orleans, LA

⁴Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana

⁵Metrohealth, Cleveland, OH

⁶Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

⁷Renal, Electrolyte, and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, PA

⁸Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD

⁹Section of Vascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

¹⁰Department of Nephrology, University of Illinois, Chicago, IL

¹¹Department of Medicine, University of Maryland, Baltimore, MD

¹²Department of Medicine, Johns Hopkins University, Baltimore, MD

Abstract

Background and Purpose—Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular events. However, the impact of CKD on cerebrovascular disease is less well understood. We hypothesized that renal function severity would be predictive of stroke risk, independent of other vascular risk factors.

*Address correspondence to: Danielle Sandsmark, M.D., Ph.D., Department of Neurology, University of Pennsylvania Perelman School of Medicine, 3400 Spruce Street, 3W Gates Building, Philadelphia, PA 19104. Phone: (215) 662-6738; Fax: 215-349-5579; danielle.sandsmark@uphs.upenn.edu.

DISCLOSURES

None of the authors report any financial conflict with the content of this manuscript. Dr. Jaar has received an honorarium from UpToDate for an unrelated medical chapter.

Methods—The study population included 3939 subjects enrolled in the Chronic Renal Insufficiency Cohort (CRIC) study, a prospective observational cohort. Stroke events were reported by participants and adjudicated by two vascular neurologists. Cox proportional hazard models were used to compare measures of baseline renal function with stroke events. Multivariable analysis was performed to adjust for key covariates.

Results—In 3939 subjects, 143 new stroke events (0.62 events per 100 person-years) occurred over a mean follow-up of 6.4 years. Stroke risk was increased in subjects who had worse baseline measurements of renal function (estimated glomerular filtration rate (eGFR) and total proteinuria or albuminuria). When adjusted for variables known to influence stroke risk, total proteinuria or albuminuria, but not eGFR, were associated with an increased risk of stroke. Treatment with blockers of the renin-angiotensin system did not decrease stroke risk in individuals with albuminuria.

Conclusions—Proteinuria and albuminuria are better predictors of stroke risk in patients with chronic kidney disease than eGFR. The impact of therapies targeting proteinuria/albuminuria in individuals with CKD on stroke prevention warrants further investigation.

Keywords

stroke; kidney disease; albuminuria; risk factor

INTRODUCTION

Chronic kidney disease (CKD), characterized by reduced kidney function or kidney damage for at least 3 months¹ affects more than 11% of adults in the United States.² CKD is often associated with other chronic diseases, such as hypertension and diabetes, and is independently associated with an increased risk of cardiovascular events.³ Furthermore, individuals with CKD have worse functional outcomes and increased mortality following cardiovascular events.³ Thus, CKD imposes a significant disease burden, both for individuals suffering from the disease and on the healthcare system as a whole.

While the association between CKD and cardiovascular risk has been well established, the impact of CKD on cerebrovascular disease is less well characterized. Certainly, kidney disease and stroke share traditional cardiovascular risk factors, including diabetes, hypertension, obesity, and smoking. The kidney and brain may be uniquely susceptible to vasculature insults given that the two rely on similar microvasculatures that allow for continuous high volume perfusion. Most of the studies which have identified an increased risk of stroke in patients with CKD have been retrospective cohorts data and meta-analyses.^{4–7} The few prospective studies of the relationship between CKD and stroke report on either specific underlying causes of CKD, such as diabetes⁸, or patients undergoing maintenance hemodialysis.^{9,10} The generalizability of these results to the larger population with CKD is uncertain. Individuals who have kidney dysfunction at the time of a stroke event have worse outcomes^{11,12}, though whether kidney dysfunction was a causative factor in the stroke mechanism is unclear. Together, these data suggest that CKD may have important implications for risk of stroke and sequelae.

The Chronic Renal Insufficiency Cohort (CRIC) study was established in 2001 to prospectively follow patients with CKD from a variety of underlying causes to better understand the relationship between progressive renal disease and cardiovascular disease.¹³ We hypothesized that a lower level of kidney function at baseline is associated with an increased risk of stroke, independent of other vascular risk factors. We also hypothesized that use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), which decrease urinary albumin excretion¹⁴, would also be associated with a reduced risk of stroke.

METHODS

Study population

The CRIC study is a prospective multicenter observational cohort of adults with moderate to advanced CKD that aims to evaluate risk factors for progression of CKD and cardiovascular disease. The study design and methods have been described in detail previously.¹³ The protocol was approved at each center's institutional review board and all patients provided informed consent. Briefly, 7 clinical centers recruited adults aged 21–74 years who had CKD but were not on dialysis using age-based eGFR inclusion criteria. All patients had eGFR ≥ 20 ml/min/1.73m² at baseline; older patients were required to have the lowest baseline eGFR to avoid inclusion of subjects with age-related declines in eGFR.¹³ Fifty percent of study participants had diabetes. Study recruitment was conducted by the individual clinical centers and recruited an ethnically and racially diverse study population. Subjects were followed prospectively until death or study dropout. Exclusion criteria included a diagnosis of polycystic kidney disease, prior dialysis treatment, prior organ/bone marrow transplant, immunotherapy for renal disease or systemic vasculitis affecting the kidneys in the prior 6 months, chemotherapy/ alkylating agents for systemic cancer (other than non-melanoma skin cancer) within 2 years prior to study enrollment, prior diagnosis of multiple myeloma or renal carcinoma, New York Heart Association class III or IV heart failure at baseline, known diagnosis of cirrhosis or HIV/AIDs, women pregnant or breast-feeding, participants in active interventional clinical trials, or those unable or unwilling to provide informed consent. Proteinuria and albuminuria was quantified by 24-hour urine collection measured at the first study visit. Information on medication use was obtained by self-report at annual clinic visits and semi-annual phone interviews.

Stroke outcomes

Participants or their proxies were contacted every 6 months about possible cardiovascular hospitalizations as well as outpatient cardiovascular tests or interventions. Stroke was defined as a fixed neurologic deficit lasting >24 h due to a presumed vascular cause. For all potential stroke events, reported either by the subject or their physicians, the medical records were independently reviewed and adjudicated by two vascular neurologists and classified as definite/probable stroke, or no stroke. Strokes were classified as ischemic or hemorrhagic using all available information from medical records and imaging studies.

Statistical methods

The baseline eGFR measurements, collected within 3 months of study recruitment, of participants who suffered a fatal and non-fatal stroke event during the follow-up period were compared to those who remained stroke free. Cox proportional hazard models were used to calculate hazard ratios and 95% confidence intervals for time to first stroke after study enrollment associated with baseline glomerular filtration rate and other markers of renal function, including 24 hour proteinuria and albuminuria.

Multivariable analysis was performed to adjust for key covariates, defined as those associated with stroke in univariate analysis at a $p < 0.05$ level, and *a priori* included age, sex, and race. Each indicator of renal impairment (eGFR, proteinuria, and albuminuria) was first analyzed separately with adjustment for these covariates. Next, eGFR and albuminuria were included simultaneously. Finally, use of ACEIs or ARBs was included in the models as a potential disease-modifying therapy.

All analyses were performed using SAS software. All statistical tests were two-sided and a result was considered significant if $p < 0.05$.

RESULTS

Subject characteristics

Baseline characteristics are summarized in Table 1. Among 3939 participants in the present CRIC analysis with a median follow-up of 6.4 years, 143 stroke events were identified in 143 patients (incidence rate: 0.62 per 100 person-years). Of the 143 stroke events, 118 were ischemic strokes while the remaining 25 were intracerebral hemorrhages. Participants who suffered stroke were older, were more likely to be black, and were more likely to have a history of diabetes, prior myocardial infarction or stroke, were active smokers, and used alcohol (Table 1). The systolic blood pressure at the baseline study visit was higher in patients who subsequently had a stroke. The reported use of medications that may modify stroke risk, including aspirin, statin drugs, erythropoietin, or blockers of the renin-angiotensin system were not different between groups (Table 1). During the follow-up period, there were 716 deaths (18.2%) and 205 patients (2.1%) who withdrew consent or were lost to follow-up.

Kidney function and stroke

Baseline kidney function measures included eGFR, total protein excreted in 24 hours and albumin excretion in 24 hours (Table 2). Characteristics of subject groups based on kidney function measurements are included in supplemental tables 1–3.

Mean baseline eGFR measurements were lower in participants who experienced a stroke event as compared to those who did not, while proteinuria/albuminuria was increased in subjects with strokes (Table 2). When subjects were categorized into groups based on baseline eGFR (Table 3), there was a significantly greater risk of stroke in patients in the lowest categories of kidney function ($\text{eGFR} < 45 \text{ ml/min/1.73m}^2$) as compared to those with the highest kidney function ($\text{eGFR} > 60 \text{ ml/min/1.73m}^2$). In this regard, there was a dose-

response relationship whereby increasing urinary protein or albumin excretion was associated with an increased risk of stroke (Table 3).

After adjustment for age, race, sex, vascular risk factors (including diabetes, systolic blood pressure, hyperlipidemia, smoking and alcohol use) and medications which modify urinary protein excretion (use of ACEI/ARBs) was performed. When these variables were controlled for, eGFR was no longer associated with a risk of stroke events (Table 4). In contrast, proteinuria >0.50 g/day or albuminuria >30 mg/day were associated with a significant increase in stroke risk after accounting for these other stroke risk factors (Table 4; Figure 1A).

Finally, when both eGFR and albuminuria were included simultaneously in the model (Table 5), albuminuria remained significantly associated with stroke risk, as did many known vascular risk factors, including age, black race, diabetes, systolic blood pressure, current smoking, and alcohol use.

Self-reported use of either an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) did not modify the risk of stroke in individuals with albuminuria (Figure 1B).

DISCUSSION

The CRIC study cohort provides a unique opportunity to assess the relationship between CKD and stroke risk using a variety of measures of kidney disease severity.

CKD is associated with cardiovascular disease as well as all-cause and cardiovascular-related mortality.¹⁵ In routine clinical practice, the degree of kidney dysfunction is typically determined by measuring serum creatinine and calculating creatinine-based eGFR. However, serum creatinine is influenced by age, sex, and lean muscle mass, confounding the associations between creatinine-based eGFR measurements and outcomes. Proteinuria and albuminuria are alternative and complementary measures of renal function that measure injury to the renal filtration barrier.^{16–18} Our study, performed in a large, diverse cohort of patients with CKD of a variety of underlying causes, indicate that small increases in protein and/or albumin excretion are associated with an increased risk of stroke. By contrast, eGFR was not associated with stroke risk after accounting for the most common vascular risk factors. This suggests that eGFR measurements alone are a poor biomarker of cerebrovascular risk in patients with CKD.

Several prior studies found that subjects with a decreased eGFR had an increased risk of stroke when compared to subjects with normal eGFR (>60 ml/min/1.73m²). Lee et al.⁶ performed a meta-analysis that found that decreased eGFR (<60 ml/min/1.73m²) was associated with an increased risk of stroke. Similarly, Piccini et al.¹⁹ found that eGFR<60 ml/min/1.73m² increased the risk of stroke in individuals with atrial fibrillation who were not on anticoagulation therapy. These studies differ from CRIC cohort in that all subjects in the CRIC cohort had existing renal dysfunction at the time of study enrollment as determined by age-based eGFR enrollment criteria¹³ (supplemental table 1). In these individuals with known kidney dysfunction, proteinuria and albuminuria are more sensitive

to stroke risk than eGFR measurement alone. In this regard, proteinuria was associated with an increased risk of stroke in patients with atrial fibrillation not treated with anticoagulation even after accounting for a decrease in eGFR.²⁰

These data support recent evidence suggesting that albuminuria may be a more sensitive biomarker for incident cardiovascular events in the general population^{15,21} and in certain disease states, such as diabetes²², than other markers of kidney disease such as eGFR. Our study extends this finding to cerebrovascular disease and suggests that albuminuria can be used to predict the risk of stroke in individuals with known CKD. Prior studies have found an association of albuminuria with incident stroke in the general population^{23–26}, but this is the first study to assess the association of renal biomarkers with stroke risk specifically in individuals with CKD. Our study bolsters these earlier reports in a diverse sample of patients with CKD from a variety of etiologies.

In addition to the conventional vascular risk factors that are common in patients with CKD, there may be pathophysiologic mechanisms unique to CKD that predispose patients to cardiovascular and cerebrovascular events. Reduced kidney function has been associated with inflammation, thromboembolism, endothelial dysfunction, and arterial stiffness/calcification and other factors, all of which may contribute to stroke risk.^{27–29} The kidney and brain both have low-resistance microvasculatures exposed to high volume, continuous perfusion. Small vessel cerebrovascular disease in the brain is mediated by endothelial dysfunction, arteriosclerosis, and blood-brain barrier disruption. Similarly, kidney dysfunction is associated with endothelial dysfunction and lipohyalinosis, both features of small vessel disease.³⁰ In fact, CKD has been associated with subclinical white matter abnormalities, suggesting that the two may share similar pathogenic mechanisms.³¹

Albumin is a large protein that is normally excreted by the kidney at very low levels (<30 mg/day) with 99% of filtered albumin being reabsorbed, such that less than 1% reaches the urine.³² Albuminuria, therefore, reflects either an increase in the filtered albumin load or a decrease in the tubular reabsorption capacity and, in that way, has been proposed as a marker of glomerular damage.³³ Further studies have suggested that, in addition to reflecting glomerular injury, albumin secretion is also pathogenic, leading to proinflammatory and profibrotic events within the proximal tubule.^{34–35} While the mechanisms by which albuminuria is associated with cardiovascular events are not fully understood, it has been postulated that albuminuria may reflect systemic endothelial dysfunction^{36–37} that alters inflammatory and thrombotic cascades^{38–39} and contributes to atherothrombotic events, including stroke.

Albuminuria has important implications as a biomarker for stroke risk in CKD, as it is a modifiable risk factor. Angiotensin converting enzyme inhibitors and angiotensin receptor blocker agents have been shown to decrease albuminuria in individuals with diabetes and hypertension⁴⁰ and decrease cardiovascular events in these patients.² Our data suggest that albuminuria severity may be useful to stratify patients with CKD who are at higher risk of suffering a cerebrovascular event and may aid in identifying individuals in whom therapy should be intensified. When we looked specifically at the use of ACEI/ARBs, there was a

suggestion patients with mild albuminuria (30–299 mg/day; Figure 1B) might benefit from ACEI/ARB therapy, though this failed to reach statistical significance.

Limitations of our study include the relatively few strokes observed in the CRIC cohort, precluding examination of differential associations of proteinuria with subtypes of stroke. The incidence of stroke in our population is similar to that reported in other studies of stroke in patients with kidney dysfunction.²³ Medical history and medication use were self-reported by participants. Medication indication, compliance and/or effectiveness were not assessed. In addition, we used medication use data collected at the first study visit; changes in medication use and dose titrations were not included in the analysis. In our study, there were a small number of hemorrhagic strokes (n=25) as compared to ischemic strokes (n=118). In our analysis, we considered all strokes together. The small number of hemorrhagic stroke limited our ability to determine which factors were associated with this specific stroke type. To patients and their providers, identifying risk factors for all potential types of strokes is important and thus we chose to analyze all strokes together. As additional stroke events accrue over time, it may be possible to determine risk factors for ischemic or hemorrhagic stroke separately in patients with kidney dysfunction.

In conclusion, the CRIC cohort study supports the growing body of evidence that proteinuria is a biomarker for cardiovascular risk and extends these findings to include proteinuria and albuminuria as markers of cerebrovascular risk in subjects with CKD. These data suggest that therapies aimed at treating proteinuria/albuminuria may be worthy of further investigation for stroke prevention. In addition, the longitudinal study of the CRIC cohort will allow us to further examine how changes in albuminuria and renal function over the 10 year planned follow-up time influence stroke risk.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

CRIC study investigators not listed as authors on this manuscript include Alan S. Go, MD, James P. Lash, MD, Akinlolu Ojo, MD, PhD, Lawrence Appel, MD, MPH, and Mahboob Rahman, MD, MS.

FUNDING

Funding for the CRIC Study was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition, this work was supported in part by: the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS UL1TR000003, Johns Hopkins University UL1 TR-000424, University of Maryland GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHHR).

References

1. National Kidney Disease Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease. Part 4: Definition and classification of stages of chronic kidney disease. *Am J Kidney Dis*. 2002; 39:S46–S75.

2. Levey AS, Coresh J. Chronic kidney disease. *Lancet*. 2012; 379:165–180. [PubMed: 21840587]
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004; 351:1296–1305. [PubMed: 15385656]
4. Ninomiya T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M, et al. Proteinuria and stroke: a meta-analysis of cohort studies. *Am J Kidney Dis*. 2009; 53:417–425. [PubMed: 19070947]
5. Abramson JL, Jurkovic CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. *Kidney Int*. 2003; 64:610–615. [PubMed: 12846757]
6. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. *BMJ*. 2010; 341:c4249. [PubMed: 20884696]
7. Słowik A, Turaj W, Iskra T, Strojny J, Szczudlik A. Microalbuminuria in nondiabetic patients with acute ischemic stroke: prevalence, clinical correlates, and prognostic significance. *Cerebrovasc Dis*. 2002; 14:15–21. [PubMed: 12097846]
8. Bouchi R, Babazono T, Nyumura I, Toya K, Hayashi T, Ohta M, et al. Is a reduced estimated glomerular filtration rate a risk factor for stroke in patients with type 2 diabetes? *Hypertens Res*. 2009; 32:381–386. [PubMed: 19325564]
9. Sozio SM, Armstrong PA, Coresh J, Jaar BG, Fink NE, Plantinga LC, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. *Am J Kidney Dis*. 2009; 54:468–477. [PubMed: 19376618]
10. Pai MF, Hsu SP, Peng YS, Hung KY, Tsai TJ. Hemorrhagic stroke in chronic dialysis patients. *Ren Fail*. 2004; 26:165–170. [PubMed: 15287201]
11. Ovbiagele B. Chronic kidney disease and risk of death during hospitalization for stroke. 2011; 301:46–50.
12. Yahalom G, Schwartz R, Schwammenthal Y, Merzeliak O, Toashi M, Orion D, et al. Chronic kidney disease and clinical outcome in patients with acute stroke. *Stroke*. 2009; 40:1296–1303. [PubMed: 19182072]
13. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. *J Am Soc Nephrol*. 2003; 14:S148–53. [PubMed: 12819321]
14. Van de Wal RMA, Voors AA, Gansevoort RT. Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management. *Expert Opin Pharmacother*. 2006; 7:2505–2520. [PubMed: 17150005]
15. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet*. 2010; 375:2073–2081. [PubMed: 20483451]
16. Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. *Am J Kidney Dis*. 2014; 63:820–834. [PubMed: 24485147]
17. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. *JAMA*. 2011; 305:1545–1552. [PubMed: 21482744]
18. Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C versus creatinine in determining risk based on kidney function. *N Engl J Med*. 2013; 369:932–943. [PubMed: 24004120]
19. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF and ATRIA study cohorts. *Circulation*. 2013; 127:224–232. [PubMed: 23212720]
20. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation study. 2009; 119:1363–1369.

21. Smink PA, Lambers Heerspink HJ, Gansevoort RT, de Jong PE, Hillege HL, Bakker SJL, et al. Albuminuria, Estimated GFR, Traditional Risk Factors, and Incident Cardiovascular Disease: The PREVEND (Prevention of Renal and Vascular Endstage Disease) Study. *Am J Kidney Dis.* 2012; 60:804–811. [PubMed: 22835901]
22. Bouchi R, Babazono T, Yoshida N, Nyumura I, Toya K, Hayashi T, et al. Association of albuminuria and reduced estimated glomerular filtration rate with incident stroke and coronary artery disease in patients with type 2 diabetes. *Hypertens Res.* 2010; 33:1298–1304. [PubMed: 20882027]
23. Lee M, Saver JL, Chang K-H, Ovbiagele B. Level of albuminuria and risk of stroke: systematic review and meta-analysis. *Cerebrovasc Dis.* 2010; 30:464–469. [PubMed: 20733300]
24. Mahmoodi BK, Yatsuya H, Matsushita K, Sang Y, Gottesman RF, Astor BC, et al. Association of kidney disease measures with ischemic versus hemorrhagic strokes: pooled analyses of 4 prospective community-based cohorts. *Stroke.* 2014; 45:1925–1931. [PubMed: 24876078]
25. Aguilar MI, O'Meara ES, Seliger S, Longstreth WT, Hart RG, Pergola PE, et al. Albuminuria and the risk of incident stroke and stroke types in older adults. *Neurology.* 2010; 75:1343–1350. [PubMed: 20810996]
26. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. *J Intern Med.* 2004; 255:247–256. [PubMed: 14746562]
27. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. *Circulation.* 2003; 107:87–92. [PubMed: 12515748]
28. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant.* 2003; 18:1731–1740. [PubMed: 12937218]
29. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? *J Am Coll Cardiol.* 2002; 39:695–701. [PubMed: 11849871]
30. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. *J Am Soc Nephrol.* 2002; 13:806–816. [PubMed: 11856789]
31. Yao H, Takashima Y, Hashimoto M, Uchino A, Yuzuriha T. Subclinical cerebral abnormalities in chronic kidney disease. *Contrib Nephrol.* 2013; 179:24–34. [PubMed: 23652446]
32. Gekle M. Renal tubule albumin transport. *Annu Rev Physiol.* 2005; 67:573–594. [PubMed: 15709971]
33. Burton C, Harris KP. The role of proteinuria in the progression of chronic renal failure. *Am J Kidney Dis.* 1996; 27:765–775. [PubMed: 8651239]
34. Bruzzi I, Benigni A, Remuzzi G. Role of increased glomerular protein traffic in the progression of renal failure. *Kidney Int Suppl.* 1997; 62:S29–31. [PubMed: 9350674]
35. Chen L, Wang Y, Tay YC, Harris DC. Proteinuria and tubulointerstitial injury. *Kidney Int Suppl.* 1997; 61:S60–2. [PubMed: 9328968]
36. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. *Lancet.* 1994; 344:14–18. [PubMed: 7912295]
37. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. *Clin Sci.* 1995; 88:629–633. [PubMed: 7634745]
38. Shen L, Lu G, Dong N, Jiang L, Ma Z, Ruan C. Von Willebrand factor, ADAMTS13 activity, TNF- α and their relationships in patients with chronic kidney disease. *Exp Ther Med.* 2012; 3:530–534. [PubMed: 22969924]
39. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T, et al. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. *Arterioscler Thromb Vasc Biol.* 1996; 16:455–461. [PubMed: 8630673]

40. Galle J. Reduction of proteinuria with angiotensin receptor blockers. *Nat Clin Pract Cardiovasc Med.* 2008; 5 (Suppl 1):S36–43. [PubMed: 18580865]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.

(A) Kaplan-Meier curves of stroke-free survival according to degree of albuminuria. (B) Risk of stroke in subjects with albuminuria and treatment with inhibitors of the renin-angiotensin system (ACEI/ARB). Error bars indicate 95% confidence intervals.

Table 1

Baseline Patient Characteristics

	Stroke (n=143)	No stroke (n=3796)	<i>p</i> value
Age (years)	61 ± 8	58 ± 11	<0.001
Race (white)	42 (29%)	1596 (42%)	<0.001
Sex (male)	61%	55%	0.14
Systolic blood pressure (mmHg)	138 ± 24	128 ± 22	<0.001
Medical history			
Hyperlipidemia	87%	82%	0.09
Diabetes	61%	48%	0.003
Cardiac arrhythmia	15%	17%	0.47
Cardiovascular dx *	57%	33%	<0.001
Peripheral vascular dx	14%	6%	<0.001
Social history			
Current smoker	24%	13%	<0.001
Alcohol use	51%	63%	0.003
Medication use			
Aspirin	50%	43%	0.09
Statin	59%	55%	0.28
Erythropoiesis-stimulating agents	4%	4%	0.90
ACEI/ARB	76%	69%	0.75

* Cardiovascular disease includes a self-reported history of coronary artery disease, prior myocardial infarction or stroke, or heart failure.

Table 2**Baseline Kidney Function Measures**

	Stroke (n=143)				No Stroke (n=3796)			
	Mean (std dev)	Median	Lower quartile	Upper quartile	Mean (std dev)	Median	Lower quartile	Upper quartile
eGFR	40.7 (14.0)	40.1	30.6	49.9	45.1 (16.9)	43.2	32.3	55.7
Proteinuria (g/24h)	1.7 (2.5)	0.6	0.1	2.4	1.0 (2.3)	0.2	0.1	0.9
Albuminuria (mg/24h)	1225.9 (2035.5)	347.5	40.2	1314.8	678.4 (1631.8)	60.1	9.7	536.3

* Baseline proteinuria and albuminuria data available for 132 and 133 subjects in stroke group and 3609 and 3626 subjects in the no stroke group respectively.

Table 3**Renal Function and Stroke Risk**

	Stroke (n=143)	No stroke (n=3796)	Hazard Ratio (95%CI)	p value	Incidence rate (per 1000 person years)
eGFR category (mL/min/1.73m²)					
>60	13 (9%)	689 (18%)	(Ref)		3.0
45–<60	34 (24%)	1057 (28%)	1.7 (0.91–3.26)	0.09	5.1
30–<45	63 (44%)	1276 (34%)	2.8 (1.52–5.01)	<0.001	8.2
<30	33 (23%)	774 (20%)	2.6 (1.37–4.95)	0.004	7.8
Urine protein (g/24h)					
<0.10	27 (21%)	1348 (37%)	(Ref)		3.2
0.10–<0.50	34 (26%)	1060 (29%)	1.6 (1.00–2.73)	0.05	5.3
0.50–<1.50	28 (21%)	554 (15%)	2.7 (1.58–4.54)	0.0003	8.6
>1.50	43 (33%)	647 (18%)	3.5 (2.17–5.69)	<0.0001	11.3
Albuminuria (mg/day)					
<30	24 (18%)	1483 (41%)	(Ref)		2.6
30–299	39 (29%)	977 (27%)	2.6 (1.54–4.25)	0.0003	6.6
300–999	31 (23%)	547 (15%)	3.6 (2.14–6.22)	<0.0001	9.5
1000	39 (29%)	619 (17%)	4.2 (2.55–7.05)	<0.0001	11.1

Table 4

Multivariable Analyses

	Hazard Ratio (95% CI)	<i>p</i> value
eGFR (mL/min/1.73m ²)		
45–<60	1.2 (0.65–2.39)	0.50
30–<45	1.7 (0.93–3.21)	0.08
<30	1.6 (0.82–3.07)	0.17
Proteinuria (g/day)		
0.10–<0.50	1.5 (0.90–2.53)	0.12
0.50–<1.50	2.2 (1.27–3.93)	0.005
1.50	3.1 (1.76–5.37)	<0.0001
Albuminuria (mg/day)		
30–299	2.2 (1.29–3.66)	0.004
300–999	3.0 (1.71–5.34)	0.0001
1000	3.6 (2.00–6.38)	<0.0001

* Each indicator of renal dysfunction is adjusted for age, sex, race, systolic blood pressure, history of hyperlipidemia, diabetes, current smoking and/or alcohol use, and ACEI/ARB use in these models, but not for each other.

Table 5

eGFR and albuminuria multivariable analysis

	Hazard Ratio (95% CI)	p value
Age	1.0 (1.02–1.06)	0.0007
Race: Black	1.5 (0.99–2.28)	0.06
Race: Other	0.9 (0.49–1.66)	0.73
Sex: Male	1.2 (0.84–1.74)	0.32
Diabetes	1.1 (0.74–1.60)	0.67
Systolic BP	1.0 (1.00–1.02)	0.007
Hyperlipidemia	1.1 (0.62–1.80)	0.84
Alcohol use	0.7 (0.49–1.01)	0.05
Current smoker	2.0 (1.32–3.08)	0.001
ACEI/ARB use	1.1 (0.74–1.66)	0.61
eGFR (ml/min/1.73m²)*		
45–<60	1.3 (0.60–2.74)	0.52
30–<45	1.7 (0.84–3.63)	0.14
<30	1.3 (0.61–2.96)	0.46
Albuminuria (mg/day)**		
30–299	2.1 (1.22–3.51)	0.007
300–999	2.8 (1.54–5.00)	0.0007
1000	3.2 (1.76–5.99)	0.0002

Variables adjusted for both eGFR and albuminuria

* eGFR adjusted for albuminuria, age, sex, systolic blood pressure, history of hyperlipidemia, diabetes, current smoking and/or alcohol use, and ACEI/ARB use

** Albuminuria adjusted for eGFR, age, sex, systolic blood pressure, history of hyperlipidemia, diabetes, current smoking and/or alcohol use, and ACEI/ARB use